Wetzikon

Researchers are evaluating the effects of a 12-week exergaming training program on people with major neurocognitive disorders (MNCD) such as Alzheimer's disease, Parkinson's disease, Lewy body dementia, or mixed dementias who live in long-term care facilities. This pilot randomized controlled trial aims to assess how exergaming influences gait speed, cognitive and motor functions, depressive symptoms, quality of life, physical activity, and sleep in these residents. Lifestyle changes that increase physical activity are known to help protect brain health, making non-drug therapies like exergaming promising options to explore. Participants will either engage in an active dance video game using the Dividat Senso device, which combines physical movement with visual, auditory, and sensory feedback, or continue with their usual care. The exergaming involves stepping on arrows displayed on a screen through body movements, with sessions lasting 15 minutes, three times a week for 12 weeks. The usual care group will receive standard support including meals, individual activities such as walking or gardening, and customized care. Throughout the study, researchers will measure physical performance using the Short Physical Performance Battery, cognitive function with the Montreal Cognitive Assessment, mood and neuropsychiatric symptoms, quality of life, daily living activities, sleep quality, and physical activity levels using motion sensors and sleep monitoring devices. Assessments occur at the start and end of the 12-week period to compare changes. Safety and health status will be monitored to ensure participants can safely engage in the program.

This research aims to assess the long-term outcomes, performance, and safety of the BIOMONITOR III implantable cardiac monitors (ICMs) and their possible successors in real-life clinical settings. The study also serves as a platform for additional scientific and regulatory investigations with minimal extra effort for both clinical sites and patients. It focuses on patients with conditions such as tachycardia, atrial fibrillation, syncope, bradycardia, and cryptogenic stroke. Participants will receive a BIOTRONIK Implantable Cardiac Monitor and use the CardioMessenger device as part of the BIOTRONIK Home Monitoring system. The study observes routine clinical care with these devices and may include submodules for further research. The timeline includes monitoring the time to diagnosis starting from the device insertion. Throughout the study, participants will be regularly monitored using the implanted device and home monitoring technology. Researchers will track outcomes related to device performance, safety, and the time it takes to reach relevant diagnoses. Participants provide informed consent and agree to use the home monitoring system during the study period, contributing to long-term data collection and safety assessment.